----

| x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|--------------------------------------------------------------------------------------|

| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|------------------------------------------------------------------------------------------|

| Delaware                                                      | 13-3379479                              |
|---------------------------------------------------------------|-----------------------------------------|
| (State or other jurisdiction ofincorporation or organization) | (I.R.S. Employer Identification Number) |

| Securities registered pursuant to Section 12(b) of the Act: |
|-------------------------------------------------------------|
| Title of each class                                         | Name of each exchange on which registered |
| Common Stock, par value $0.0013 per share                   | The NASDAQ Stock Market LLC |

| Securities registered pursuant to Section 12(g) of the Act: | None |
|-------------------------------------------------------------|------|

| Large accelerated filer  ¨                                                          | Accelerated filer   x              |
|-----------------------------------------------------------------------------------------------|----------------------------------------------|
| Non-accelerated filer    ¨  (Do not check if a smaller reporting company) | Smaller reporting company   ¨ |

|  | (1) | Calculated by excluding all shares that may be deemed to be beneficially owned by executive officers, directors and five percent stockholders of the Registrant, without conceding that any such person is an "affiliate" of the Registrant for purposes of the Federal securities laws. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| PART I                                     |                                                                                                         |   |
|--------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------|
| Item 1.                                    | Business                                                                                                     | 2      |
| Item 1A.                                   | Risk Factors                                                                                                 | 12     |
| Item 1B.                                   | Unresolved Staff Comments                                                                                    | 25     |
| Item 2.                                    | Properties                                                                                                   | 25     |
| Item 3.                                    | Legal Proceedings                                                                                            | 25     |
| Item 4.                                    | Not Applicable                                                                                               | 25     |
| PART II                                    |                                                                                                         |   |
| Item 5.                                    | Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 25     |
| Item 6.                                    | Selected Financial Data                                                                                      | 27     |
| Item 7.                                    | Management's Discussion and Analysis of Financial Condition and Results of Operations                        | 28     |
| Item 7A.                                   | Quantitative and Qualitative Disclosures about Market Risk                                                   | 39     |
| Item 8.                                    | Financial Statements and Supplementary Data                                                                  | 39     |
| Item 9.                                    | Changes in and Disagreements With Accountants on Accounting and Financial Disclosure                         | 39     |
| Item 9A.                                   | Controls and Procedures                                                                                      | 39     |
| Item 9B.                                   | Other Information                                                                                            | 41     |
| PART III                                   |                                                                                                         |   |
| Item 10.                                   | Directors, Executive Officers and Corporate Governance                                                       | 42     |
| Item 11.                                   | Executive Compensation                                                                                       | 42     |
| Item 12.                                   | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters               | 42     |
| Item 13.                                   | Certain Relationships and Related Transactions, and Director Independence                                    | 42     |
| Item 14.                                   | Principal Accounting Fees and Services                                                                       | 42     |
| PART IV                                    |                                                                                                         |   |
| Item 15.                                   | Exhibits, Financial Statement Schedules                                                                      | 43     |
| INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | F-1                                                                                                          |
| SIGNATURES                                 | S-1                                                                                                          |
| EXHIBIT INDEX                              | E-1                                                                                                          |

----

Table of Contents

----

Table of Contents

|                            |        |                                                                                                                                                     |        |                                                                                                                             |
|---------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------|
| OUR PRODUCT CANDIDATES          |   |                                                                                                                                                |   |                                                                                                                        |
|                            |   |                                                                                                                                                |   |                                                                                                                        |
|                            |   | In development for                                                                                                                                  |   | Status                                                                                                                      |
|                            |
| PSMA ADC                        |   | Treatment of prostate cancer                                                                                                                        |   | Phase 2 testing in chemotherapy-experienced patients completed; a second cohort in chemotherapy-naïve patients ongoing |
|                            |   |                                                                                                                                                |   |                                                                                                                        |
| 1404                            |   | Imaging agent for prostate cancer                                                                                                                   |   | Phase 2 testing completed                                                                                                   |
|                            |   |                                                                                                                                                |   |                                                                                                                        |
| Azedra™                   |   | Treatment of pheochromocytoma and paraganglioma                                                                                                     |   | Phase 2b registrational trial under Special Protocol Assessment (SPA)                                                       |
|                            |   |                                                                                                                                                |   |                                                                                                                        |
| RELISTOR®                  |   |                                                                                                                                                |   |                                                                                                                        |
|                            |   |                                                                                                                                                |   |                                                                                                                        |
| Relistor-Subcutaneous injection |   | Treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient |   | Marketed in the U.S., E.U., Canada, Australia and elsewhere; licensed to Salix Pharmaceuticals                              |
|                            |   |                                                                                                                                                |   |                                                                                                                        |
| Relistor-Subcutaneous injection |   | Treatment of OIC in patients with non-cancer pain                                                                                                   |   | Complete Response Letter received in 2012 on pending sNDA; awaiting meeting date of Advisory Committee convened by FDA      |
|                            |   |                                                                                                                                                |   |                                                                                                                        |
| Relistor-Oral                   |   | Treatment of OIC                                                                                                                                    |   | Phase 3 testing completed                                                                                                   |
|                            |   |                                                                                                                                                |   |                                                                                                                        |
|                            |   |                                                                                                                                                |   |                                                                                                                        |

| · | PSMA ADC, a fully human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. In a phase 2 open-label, multicenter clinical trial to assess anti-tumor activity, tolerability and safety, we have completed enrollment in an original cohort of chemotherapy refractory patients with metastatic castration-resistant prostate cancer (mCRPC) and are conducting a second cohort of chemotherapy-naïve patients. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | 1404 (trofolastat), a radio-labeled small molecule which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer, including metastases in other soft tissue and bone. We have recently completed a global multicentered phase 2 study assessing the diagnostic accuracy of 1404 imaging in men with high-risk prostate cancer scheduled for radical prostectomy. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Azedra, a phase 2 radiotherapeutic product candidate in development as a treatment for pheochromocytoma -- rare tumors found primarily in the adrenal glands – and related paraganglioma tumors occurring in other tissues. Azedra has Orphan Drug designation and Fast Track status in the U.S. for pheochromocytoma and paraganglioma, with clinical study conducted under a 2009 Special Protocol Assessment (SPA) with the FDA. There is currently no FDA-approved therapeutic for the treatment of pheochromocytoma. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|             |   | FirstQuarter |   |   | SecondQuarter |   |   | ThirdQuarter   |   |   | FourthQuarter |   |   | FullYear |   |
|------------------|--------|--------------|--------|--------|---------------|--------|--------|----------------|--------|--------|---------------|--------|--------|----------|--------|
|             |   |              |   |   |               |   |   | (in thousands) |   |   |               |   |   |          |   |
| 2013:            |   |              |   |
| Net Sales        |   | $            | 7,700  |   |          | $      | 7,900  |           |   | $      | 4,800         |   |   | $        | 19,000 |   |   | $ | 39,400 |   |
| Royalties Earned |   |         | 1,155  |   |          |   | 1,174  |           |   |   | 719           |   |   |     | 2,847  |   |   |   | 5,895 |   |
| 2012:            |   |              |   |
| Net Sales        |   | $            | 12,300 |   |          | $      | 10,800 |           |   | $      | 4,900         |   |   | $        | 5,200  |   |   | $ | 33,200 |   |
| Royalties Earned |   |         | 1,834  |   |          |   | 1,619  |           |   |   | 728           |   |   |     | 782    |   |   |   | 4,963 |   |
| 2011:            |   |              |   |
| Net Sales        |   | $            | 3,300  |   |          | $      | 5,200  |           |   | $      | 9,700         |   |   | $        | 8,800  |   |   | $ | 27,000 |   |
| Royalties Earned |   |         | -      |   |          |   | 527    |           |   |   | 1,240         |   |   |     | 1,279  |   |   |   | 3,046 |   |

----

Table of Contents

----

Table of Contents

| · | A 2012 co-exclusive license agreement with the University of Zurich and the Paul Scherrer Institute for worldwide sublicensable rights to certain intellectual property related to production methodologies relevant to 1404. Under this agreement, we maintain related patent rights and are obligated to pay low single-digit royalties on products using the licensed technology, license maintenance fees creditable against royalties, an annual fee for an option to expand the license's field of use, and clinical and regulatory milestone payments aggregating approximately $1.2 million. The agreement may be terminated by the licensors upon certain material defaults by, and automatically terminates upon certain bankruptcy events relating to Molecular Insight, and may be terminated by us on prior written notice. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | A 2000 exclusive license agreement with The University of Western Ontario for worldwide sublicensable rights to certain intellectual property related to production methodologies relevant to Azedra. Under this agreement, we maintain related patent rights and are obligated to pay low single-digit royalties on products using the licensed technology, minimum annual royalties creditable against royalties and clinical and regulatory milestone payments aggregating approximately $0.2 million. The agreement, which either party may terminate upon certain bankruptcy events or material defaults, continues through the last to expire of the related patent rights. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | A 2006 agreement with Novartis Pharma AG for exclusive rights to certain technology relating to Onalta™, a compound which has been outlicensed to third parties which are obligated to make milestone payments and royalties consistent with Molecular's obligations under this agreement, including royalties and milestone payments, partially creditable against future royalties, totaling $4.6 million upon the attainment of certain regulatory approvals. Either party may terminate this agreement immediately upon the occurrence of bankruptcy proceedings relating to or in the event of an uncured material breach by the other party, and Novartis may terminate in the event Molecular Insight is acquired by a direct competitor of Novartis. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| Clinical and Research |   | Number of Patents |   | Expiration    |   | Number of Patent Applications |
|-----------------------|--------|-------------------|--------|---------------|--------|-------------------------------|
| Candidates; Relistor  |   | U.S.              |   | International |   | Dates (1)                     |   | U.S. |   | International |
|                  |   |              |   |          |   |                          |   |   |   |   |
| Development programs  |   | 21                |   | 76            |   | 2015-2031                     |   | 15 |   | 49 |
|                  |   |              |   |          |   |                          |   |   |   |   |
| Relistor              |   | 19                |   | 112           |   | 2015-2031                     |   | 23 |   | 218 |
|                  |   |              |   |          |   |                          |   |   |   |   |
| Other                 |   | 1                 |   | 1             |   | 2029                          |   | 4 |   | 19 |
|                  |   |              |   |          |   |                          |   |   |   |   |

| (1)        | Patent term extensions and pending patent applications may extend periods of patent protection. |
|-----------------------------------------------|-------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | pre-clinical laboratory and animal tests;                                                                                                                                                                                                          |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | · | submission to and favorable review by the FDA of an investigational new drug application before clinical trials may begin;                                                                                                                         |
|  | · | adequate and well-controlled human clinical trials to establish the safety and efficacy of the product for its intended indication (animal and other nonclinical studies also are typically conducted during each phase of human clinical trials); |
|  | · | submission to the FDA of a marketing application; and                                                                                                                                                                                              |
|  | · | FDA review of the marketing application in order to determine, among other things, whether the product is safe and effective for its intended uses.                                                                                                |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|   | · | It might not obtain labeling claims necessary to make the product commercially viable (in general, labeling claims define the medical conditions for which a drug product may be marketed, and are therefore very important to the commercial success of a product), or may be required to carry Boxed or other warnings that adversely affect its commercial success. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Approval may be limited to uses of the product for treatment or prevention of diseases or conditions that are relatively less financially advantageous to us than approval of greater or different scope or subject to an FDA-imposed REMS that imposes limits on the distribution or use of the product. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Side effects (including different or aggravated effects such as SAEs encountered in our PSMA ADC program) identified after the product is on the market might hurt sales or result in mandatory safety labeling changes, additional pre-clinical testing or clinical trials, imposition of a REMS, product recalls or withdrawals from the market. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Efficacy or safety concerns (including those arising from SAEs heretofore or hereafter encountered in our PSMA ADC program) regarding a marketed product, or manufacturing or other problems, may lead to a recall, withdrawal of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling, imposition of a REMS, the need for additional marketing applications, declining sales or other adverse events. These potential consequences may occur whether or not the concerns originate from subsequent testing or other activities by us, governmental regulators, other entities or organizations or otherwise, and whether or not they are scientifically justified. If products lose previously received marketing and other approvals, our business, results of operations and financial condition would be materially adversely affected. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|       |                  |   | High   |   |   | Low    |   |
|-------|-----------------------|--------|--------|--------|--------|--------|--------|
| 2013: |   Fourth quarter |   | $      | 5.90   |   |   | $      | 3.45 |   |
|       | Third quarter         |   |   | 6.47   |   |   |   | 4.36 |   |
|       | Second quarter        |   |   | 5.57   |   |   |   | 3.54 |   |
|       | First quarter         |   |   | 5.96   |   |   |   | 2.53 |   |
|       |                  |   |   |   |   |   |   |   |   |
| 2012: |   Fourth quarter |   | $      | 3.30   |   |   | $      | 1.41 |   |
|       | Third quarter         |   |   | 11.00  |   |   |   | 2.81 |   |
|       | Second quarter        |   |   | 11.34  |   |   |   | 7.44 |   |
|       | First quarter         |   |   | 10.50  |   |   |   | 8.32 |   |

----

Table of Contents

----

Table of Contents

|                                                |   | Years Ended December 31,              |    |
|-----------------------------------------------------|--------|---------------------------------------|---------|
|                                                |   | 2013                                  |    |   | 2012 |   |   | 2011 |   |   | 2010 |   |   | 2009 |   |
|                                                |   | (in thousands, except per share data) |    |
| Statement of Operations Data:                       |   |                                       |    |   |  |   |   |  |   |   |  |   |   |  |   |
| Revenues:                                           |   |                                       |    |   |  |   |   |  |   |   |  |   |   |  |   |
| Royalty income                                      |   | $                                     | 5,923   |   |   | $ | 4,963 |   |   | $ | 3,046 |   |   | $ | 1,826 |   |   | $ | 2,372 |   |
| Collaboration revenue                               |   |                                  | 1,595   |   |   |   | 8,525 |   |   |   | 76,764 |   |   |   | 1,413 |   |   |   | 44,351 |   |
| Research grants                                     |   |                                  | 275     |   |   |   | 488 |   |   |   | 4,810 |   |   |   | 4,573 |   |   |   | 1,968 |   |
| Other revenues                                      |   |                                  | 69      |   |   |   | 72 |   |   |   | 176 |   |   |   | 140 |   |   |   | 256 |   |
| Total revenues                                      |   |                                  | 7,862   |   |   |   | 14,048 |   |   |   | 84,796 |   |   |   | 7,952 |   |   |   | 48,947 |   |
| Expenses:                                           |   |                                  |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Research and development                            |   |                                  | 33,903  |   |   |   | 31,840 |   |   |   | 53,183 |   |   |   | 50,640 |   |   |   | 49,798 |   |
| License fees - research and development             |   |                                  | 567     |   |   |   | 1,170 |   |   |   | 578 |   |   |   | 1,270 |   |   |   | 1,058 |   |
| Royalty expense                                     |   |                                  | 624     |   |   |   | 499 |   |   |   | 405 |   |   |   | 241 |   |   |   | 237 |   |
| General and administrative                          |   |                                  | 14,809  |   |   |   | 14,706 |   |   |   | 18,248 |   |   |   | 22,832 |   |   |   | 25,106 |   |
| Depreciation and amortization                       |   |                                  | 939     |   |   |   | 1,324 |   |   |   | 2,066 |   |   |   | 2,853 |   |   |   | 5,078 |   |
| Total expenses                                      |   |                                  | 50,842  |   |   |   | 49,539 |   |   |   | 74,480 |   |   |   | 77,836 |   |   |   | 81,277 |   |
| Operating (loss) income                             |   |                                  | (42,980 | ) |   |   | (35,491 | ) |   |   | 10,316 |   |   |   | (69,884 | ) |   |   | (32,330 | ) |
| Other income:                                       |   |                                  |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Interest income                                     |   |                                  | 46      |   |   |   | 60 |   |   |   | 65 |   |   |   | 64 |   |   |   | 1,481 |   |
| Gain on sale of marketable securities               |   |                                  | -       |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 237 |   |
| Total other income                                  |   |                                  | 46      |   |   |   | 60 |   |   |   | 65 |   |   |   | 64 |   |   |   | 1,718 |   |
| Net (loss) income before provision for income taxes |   |                                  | (42,934 | ) |   |   | (35,431 | ) |   |   | 10,381 |   |   |   | (69,820 | ) |   |   | (30,612 | ) |
| Income tax benefit                                  |   |                                  | 362     |   |   |   | - |   |   |   | - |   |   |   | 95 |   |   |   | - |   |
| Net (loss) income                                   |   | $                                     | (42,572 | ) |   | $ | (35,431 | ) |   | $ | 10,381 |   |   | $ | (69,725 | ) |   | $ | (30,612 | ) |
| Per share amounts on net (loss) income:             |   |                                  |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Basic                                               |   | $                                     | (0.76   | ) |   | $ | (1.02 | ) |   | $ | 0.31 |   |   | $ | (2.14 | ) |   | $ | (0.98 | ) |
| Diluted                                             |   | $                                     | (0.76   | ) |   | $ | (1.02 | ) |   | $ | 0.31 |   |   | $ | (2.14 | ) |   | $ | (0.98 | ) |

|                                   |   | December 31,   |    |
|----------------------------------------|--------|----------------|---------|
|                                   |   | 2013           |    |   | 2012 |   |   | 2011 |   |   | 2010 |   |   | 2009 |   |
|                                   |   | (in thousands) |    |
| Balance Sheet Data:                    |   |                |    |   |  |   |   |  |   |   |  |   |   |  |   |
| Cash and cash equivalents              |   | $              | 65,860  |   |   | $ | 58,838 |   |   | $ | 70,105 |   |   | $ | 47,918 |   |   | $ | 90,903 |   |
| Auction Rate and marketable securities |   |           | 2,208   |   |   |   | 3,240 |   |   |   | 3,332 |   |   |   | 3,608 |   |   |   | 5,293 |   |
| Working capital                        |   |           | 64,055  |   |   |   | 58,805 |   |   |   | 65,890 |   |   |   | 42,207 |   |   |   | 95,388 |   |
| Total assets                           |   |           | 114,541 |   |   |   | 76,308 |   |   |   | 80,110 |   |   |   | 62,738 |   |   |   | 113,613 |   |
| Deferred revenue - current             |   |           | -       |   |   |   | 838 |   |   |   | 204 |   |   |   | - |   |   |   | - |   |
| Deferred revenue - long term           |   |           | -       |   |   |   | - |   |   |   | 162 |   |   |   | - |   |   |   | - |   |
| Other liabilities - long term          |   |           | 28,935  |   |   |   | 1,078 |   |   |   | 1,497 |   |   |   | 1,635 |   |   |   | - |   |
| Total stockholders' equity             |   |           | 78,979  |   |   |   | 66,568 |   |   |   | 71,801 |   |   |   | 51,308 |   |   |   | 107,607 |   |

----

Table of Contents

----

Table of Contents

|                    |   | 2013   |    |   | 2012   |   |    | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|-------------------------|--------|--------|---------|--------|--------|--------|---------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                    |   |        |    |   |        |   |    |        |   |   | Percent Change |   |
|                    |   |        |    |   |        |   |    |        |   |   |                |   |   |               |   |
| Revenues                |   | $      | 7,862   |   |   | $      | 14,048  |   |   | $      | 84,796         |   |   |          | (44    | %) |   |   | (83 | %) |
| Expenses                |   |   | (50,842 | )      |   |   | (49,539 | )      |   |   | (74,480        | )      |   |          | 3      | % |   |   | (33 | %) |
| Operating (loss) income |   |   | (42,980 | )      |   |   | (35,491 | )      |   |   | 10,316         |   |   |          | 21     | % |   |   | (444 | %) |
| Other income            |   |   | 46      |   |   |   | 60      |   |   |   | 65             |   |   |          | (23    | %) |   |   | (8 | %) |
| Income tax benefit      |   |   | 362     |   |   |   | -       |   |   |   | -              |   |   |          | 100    | % |   |   | N/ | A |
| Net (loss) income       |   | $      | (42,572 | )      |   | $      | (35,431 | )      |   | $      | 10,381         |   |   |          | 20     | % |   |   | (441 | %) |

| Sources of Revenue    |   | 2013   |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|-----------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                  |   |        |   |   |        |   |   |        |   |   | Percent Change |   |
|                  |   |        |   |   |        |   |   |        |   |   |                |   |   |               |   |
| Royalty income        |   | $      | 5,923  |   |   | $      | 4,963  |   |   | $      | 3,046          |   |   |          | 19     | % |   |   | 63 | % |
| Collaboration revenue |   |   | 1,595  |   |   |   | 8,525  |   |   |   | 76,764         |   |   |          | (81    | %) |   |   | (89 | %) |
| Research grants       |   |   | 275    |   |   |   | 488    |   |   |   | 4,810          |   |   |          | (44    | %) |   |   | (90 | %) |
| Other revenues        |   |   | 69     |   |   |   | 72     |   |   |   | 176            |   |   |          | (4     | %) |   |   | (59 | %) |
| Total                 |   | $      | 7,862  |   |   | $      | 14,048 |   |   | $      | 84,796         |   |   |          | (44    | %) |   |   | (83 | %) |

----

Table of Contents

|    |   | Relistor Net Sales Reported by Collaborators |   |
|---------|--------|----------------------------------------------|--------|
|    |   | Years Ended December 31,                     |   |
|    |   | 2013                                         |   |   | 2012 |   |   | 2011 |   |
| U.S.    |   | $                                            | 35,000 |   |   | $ | 29,200 |   |   | $ | 21,500 |   |
| Ex-U.S. |   |                                         | 4,400  |   |   |   | 4,000 |   |   |   | 5,500 |   |
| Global  |   | $                                            | 39,400 |   |   | $ | 33,200 |   |   | $ | 27,000 |   |

|                  |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|-----------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                  |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Salaries and benefits |   | $    | 12,481 |   |   | $      | 15,372 |   |   | $      | 18,658         |   |   |          | (19    | %) |   |   | (18 | %) |

----

Table of Contents

|                     |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|--------------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                     |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Share-based compensation |   | $    | 2,524  |   |   | $      | 4,568  |   |   | $      | 4,499          |   |   |          | (45    | %) |   |   | 2 | % |

|                 |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|----------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                 |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Clinical trial costs |   | $    | 8,862  |   |   | $      | 2,692  |   |   | $      | 10,099         |   |   |          | 229    | % |   |   | (73 | %) |

|                         |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|------------------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
| Laboratory and manufacturing |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| supplies and equipment       |   | $    | 632    |   |   | $      | 592    |   |   | $      | 4,203          |   |   |          | 7      | % |   |   | (86 | %) |

|                       |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|----------------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
| Contract manufacturing and |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| subcontractors             |   | $    | 2,042  |   |   | $      | 3,111  |   |   | $      | 6,713          |   |   |          | (34    | %) |   |   | (54 | %) |

----

Table of Contents

|        |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|-------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|        |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Consultants |   | $    | 905    |   |   | $      | 330    |   |   | $      | 1,270          |   |   |          | 174    | % |   |   | (74 | %) |

|         |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|--------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|         |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| License fees |   | $    | 567    |   |   | $      | 1,170  |   |   | $      | 578            |   |   |          | (52    | %) |   |   | 102 | % |

|            |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|-----------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|            |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Royalty expense |   | $    | 624    |   |   | $      | 499    |   |   | $      | 405            |   |   |          | 25     | % |   |   | 23 | % |

|                     |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|--------------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                     |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Other operating expenses |   | $    | 6,457  |   |   | $      | 5,175  |   |   | $      | 7,741          |   |   |          | 25     | % |   |   | (33 | %) |

|                  |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|-----------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                  |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Salaries and benefits |   | $    | 4,821  |   |   | $      | 6,493  |   |   | $      | 7,228          |   |   |          | (26    | %) |   |   | (10 | %) |

----

Table of Contents

|                     |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|--------------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                     |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Share-based compensation |   | $    | 1,022  |   |   | $      | 1,968  |   |   | $      | 1,863          |   |   |          | (48    | %) |   |   | 6 | % |

|                             |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|----------------------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                             |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Consulting and professional fees |   | $    | 3,922  |   |   | $      | 2,362  |   |   | $      | 4,389          |   |   |          | 66     | % |   |   | (46 | %) |

|                     |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|--------------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                     |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Other operating expenses |   | $    | 4,325  |   |   | $      | 3,883  |   |   | $      | 4,768          |   |   |          | 11     | % |   |   | (19 | %) |

|                          |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|-------------------------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|                          |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Depreciation and amortization |   | $    | 939    |   |   | $      | 1,324  |   |   | $      | 2,066          |   |   |          | (29    | %) |   |   | (36 | %) |

----

Table of Contents

|            |   | 2013 |   |   | 2012   |   |   | 2011   |   |   | 2013 vs. 2012  |   |   | 2012 vs. 2011 |   |
|-----------------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|--------|--------|---------------|--------|
|            |   |      |   |   |        |   |   |        |   |   | Percent change |   |
| Interest income |   | $    | 46     |   |   | $      | 60     |   |   | $      | 65             |   |   |          | (23    | %) |   |   | (8 | %) |

----

Table of Contents

----

Table of Contents

|           |   | 2013   |   |   | 2012   |   |   | 2011   |   |
|----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
|           |   |        |   |
| Oncology       |   | $      | 33.4   |   |   | $      | 29.1   |   |   | $ | 22.2 |   |
| Relistor       |   |   | 0.9    |   |   |   | 1.7    |   |   |   | 23.2 |   |
| Other programs |   |   | 0.8    |   |   |   | 2.7    |   |   |   | 8.8 |   |
| Total          |   | $      | 35.1   |   |   | $      | 33.5   |   |   | $ | 54.2 |   |

|                                         |   |               |   |   | Payments due by Year-end |   |
|----------------------------------------------|--------|---------------|--------|--------|--------------------------|--------|
|                                         |   | Total         |   |   | 2014                     |   |   |   | 2015-2016 |   |   |   | 2017-2018 |   |   | Thereafter |   |
|                                         |   | (in millions) |   |
| Operating leases                             |   | $             | 13.9   |   |                     | $      | 1.9 |   |   | $ | 3.8 |   |   | $ | 4.0 |   |   | $ | 4.2 |   |
| License, collaboration and other agreements: |   |          |   |   |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Fixed payments                               |   |          | 1.3    |   |                     |   | 0.3 |   |   |   | 0.4 |   |   |   | 0.6 |   |   |   | - |   |
| Contingent payments (1)                      |   |          | 105.7  |   |                     |   | - |   |   |   | 2.3 |   |   |   | 7.7 |   |   |   | 95.7 |   |
| Total                                        |   | $             | 120.9  |   |                     | $      | 2.2 |   |   | $ | 6.5 |   |   | $ | 12.3 |   |   | $ | 99.9 |   |

| (1) | Based on assumed achievement of milestones covered under each agreement, the timing and payment of which is highly uncertain. |
|-----|-------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| ·  | Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of assets;                                                                                                                                                                   |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                                                                                                                                                                                                                                         |
| ·  | Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorization of management and directors; and |
|         |                                                                                                                                                                                                                                                                                                         |
| ·  | Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.                                                                                                               |

----

Table of Contents

----

Table of Contents

| Item of Form 10-K | Location in 2014 Proxy Statement                       |
|-------------------|--------------------------------------------------------|
|              |                                                   |   |
| Item 10.          | Directors, Executive Officers and Corporate Governance | Election of Directors.Executive and Other Officers.Corporate Governance.Code of Business Ethics and Conduct.*Section 16(a) Beneficial Ownership Reporting and Compliance.*The full text of our Code of Business Ethics and Conduct is available on our website (www.progenics.com). |
|              |                                                   |   |

| Item 11. | Executive Compensation | Executive Compensation.Compensation Committee Report.Compensation Committee Interlocks and Insider Participation. |
|----------|------------------------|-------------------------------------------------------------------------------------------------------------------|
|     |                   |                                                                                                              |

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | Equity Compensation Plan Information.Security Ownership of Certain Beneficial Owners and Management. |
|----------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
|     |                                                                                           |                                                                                                 |

| Item 13. | Certain Relationships and Related Transactions, and Director Independence | Certain Relationships and Related Transactions.Affirmative Determinations Regarding Director Independence and Other Matters. |
|----------|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
|     |                                                                      |                                                                                                                         |

| Item 14. | Principal Accounting Fees and Services | Fees Billed for Services Rendered by our Independent Registered Public Accounting Firm.Pre-approval of Audit and Non-Audit Services by the Audit Committee. |
|----------|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | (a) | Documents filed as part of this Annual Report: |
|--|-----|------------------------------------------------|

|  | (b) | Financial Statement Schedules |
|--|-----|-------------------------------|

|  | (c) | Item 601 Exhibits |
|--|-----|-------------------|

----

Table of Contents

|                                                                                                        | Page   |
|-------------------------------------------------------------------------------------------------------------|--------|
| Reports of Independent Registered Public Accounting Firms                                                   | F-2    |
| Financial Statements:                                                                                       |   |
| Consolidated Balance Sheets at December 31, 2013 and 2012                                                   | F-3    |
| Consolidated Statements of Operations for the years ended December 31, 2013, 2012 and 2011                  | F-4    |
| Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2013, 2012 and 2011 | F-5    |
| Consolidated Statements of Stockholders' Equity for the years ended December 31, 2013, 2012 and 2011        | F-6    |
| Consolidated Statements of Cash Flows for the years ended December 31, 2013, 2012 and 2011                  | F-7    |
| Notes to Consolidated Financial Statements                                                                  | F-8    |

----

Table of Contents

|   |
|--------|

----

Table of Contents

|                                                                                                                                                     |   | December 31, |     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|----------|
|                                                                                                                                                     |   | 2012         |     |   | 2012 |   |
| Assets                                                                                                                                                   |   |              |     |   |  |   |
| Current assets:                                                                                                                                          |   |              |     |   |  |   |
| Cash and cash equivalents                                                                                                                                |   | $            | 65,860   |   |   | $ | 58,838 |   |
| Accounts receivable, net                                                                                                                                 |   |         | 2,879    |   |   |   | 6,937 |   |
| Other current assets                                                                                                                                     |   |         | 1,943    |   |   |   | 1,692 |   |
| Total current assets                                                                                                                                     |   |         | 70,682   |   |   |   | 67,467 |   |
| Auction rate securities                                                                                                                                  |   |         | 2,208    |   |   |   | 3,240 |   |
| Fixed assets, at cost, net of accumulated depreciation and amortization                                                                                  |   |         | 2,413    |   |   |   | 3,399 |   |
| Intangible assets, net (Note 3)                                                                                                                          |   |         | 31,379   |   |   |   | - |   |
| Goodwill                                                                                                                                                 |   |         | 7,702    |   |   |   | - |   |
| Deferred tax assets – long term                                                                                                                    |   |         | -        |   |   |   | 2,052 |   |
| Other assets                                                                                                                                             |   |         | 157      |   |   |   | 150 |   |
| Total assets                                                                                                                                             |   | $            | 114,541  |   |   | $ | 76,308 |   |
|                                                                                                                                                     |   |         |     |   |   |   |   |   |
| Liabilities and Stockholders' Equity                                                                                                                     |   |         |     |   |   |   |   |   |
| Current liabilities:                                                                                                                                     |   |         |     |   |   |   |   |   |
| Accounts payable and accrued expenses                                                                                                                    |   | $            | 6,512    |   |   | $ | 5,640 |   |
| Deferred tax liability - current                                                                                                                         |   |         | -        |   |   |   | 2,069 |   |
| Deferred revenue - current                                                                                                                               |   |         | -        |   |   |   | 838 |   |
| Other current liabilities                                                                                                                                |   |         | 115      |   |   |   | 115 |   |
| Total current liabilities                                                                                                                                |   |         | 6,627    |   |   |   | 8,662 |   |
| Contingent consideration liability                                                                                                                       |   |         | 15,700   |   |   |   | - |   |
| Deferred tax liability - long term                                                                                                                       |   |         | 12,321   |   |   |   | - |   |
| Other liabilities                                                                                                                                        |   |         | 914      |   |   |   | 1,078 |   |
| Total liabilities                                                                                                                                        |   |         | 35,562   |   |   |   | 9,740 |   |
| Commitments and contingencies (Note 10)                                                                                                                  |   |         |     |   |   |   |   |   |
| Stockholders' equity:                                                                                                                                    |   |         |     |   |   |   |   |   |
| Preferred stock, $.001 par value; 20,000,000 shares authorized; issued and outstanding – none                                                      |   |         | -        |   |   |   | - |   |
| Common stock, $.0013 par value; shares authorized - 160,000,000 in 2013 and 80,000,000 in 2012; issued – 61,025,404 in 2013 and 46,765,472 in 2012 |   |         | 79       |   |   |   | 61 |   |
| Additional paid-in capital                                                                                                                               |   |         | 548,510  |   |   |   | 493,613 |   |
| Accumulated deficit                                                                                                                                      |   |         | (466,677 | ) |   |   | (424,105 | ) |
| Accumulated other comprehensive loss                                                                                                                     |   |         | (192     | ) |   |   | (260 | ) |
| Treasury stock, at cost (200,000 shares in 2013 and 2012)                                                                                                |   |         | (2,741   | ) |   |   | (2,741 | ) |
| Total stockholders' equity                                                                                                                               |   |         | 78,979   |   |   |   | 66,568 |   |
| Total liabilities and stockholders' equity                                                                                                               |   | $            | 114,541  |   |   | $ | 76,308 |   |

----

Table of Contents

|                                                      |   | Years Ended December 31, |    |
|-----------------------------------------------------------|--------|--------------------------|---------|
|                                                      |   | 2013                     |    |   | 2012 |   |   | 2011 |   |
| Revenues:                                                 |   |                          |    |   |  |   |   |  |   |
| Royalty income                                            |   | $                        | 5,923   |   |   | $ | 4,963 |   |   | $ | 3,046 |   |
| Collaboration revenue                                     |   |                     | 1,595   |   |   |   | 8,525 |   |   |   | 76,764 |   |
| Research grants                                           |   |                     | 275     |   |   |   | 488 |   |   |   | 4,810 |   |
| Other revenues                                            |   |                     | 69      |   |   |   | 72 |   |   |   | 176 |   |
| Total revenues                                            |   |                     | 7,862   |   |   |   | 14,048 |   |   |   | 84,796 |   |
|                                                      |   |                     |    |   |   |   |   |   |   |   |   |   |
| Expenses:                                                 |   |                     |    |   |   |   |   |   |   |   |   |   |
| Research and development                                  |   |                     | 33,903  |   |   |   | 31,840 |   |   |   | 53,183 |   |
| License fees – research and development             |   |                     | 567     |   |   |   | 1,170 |   |   |   | 578 |   |
| Royalty expense                                           |   |                     | 624     |   |   |   | 499 |   |   |   | 405 |   |
| General and administrative                                |   |                     | 14,809  |   |   |   | 14,706 |   |   |   | 18,248 |   |
| Depreciation and amortization                             |   |                     | 939     |   |   |   | 1,324 |   |   |   | 2,066 |   |
| Total expenses                                            |   |                     | 50,842  |   |   |   | 49,539 |   |   |   | 74,480 |   |
|                                                      |   |                     |    |   |   |   |   |   |   |   |   |   |
| Operating (loss) income                                   |   |                     | (42,980 | ) |   |   | (35,491 | ) |   |   | 10,316 |   |
|                                                      |   |                     |    |   |   |   |   |   |   |   |   |   |
| Other income:                                             |   |                     |    |   |   |   |   |   |   |   |   |   |
| Interest income                                           |   |                     | 46      |   |   |   | 60 |   |   |   | 65 |   |
| Total other income                                        |   |                     | 46      |   |   |   | 60 |   |   |   | 65 |   |
|                                                      |   |                     |    |   |   |   |   |   |   |   |   |   |
| Net (loss) income before provision  for income taxes |   |                     | (42,934 | ) |   |   | (35,431 | ) |   |   | 10,381 |   |
|                                                      |   |                     |    |   |   |   |   |   |   |   |   |   |
| Income tax benefit                                        |   |                     | 362     |   |   |   | - |   |   |   | - |   |
|                                                      |   |                     |    |   |   |   |   |   |   |   |   |   |
| Net (loss) income                                         |   | $                        | (42,572 | ) |   | $ | (35,431 | ) |   | $ | 10,381 |   |
|                                                      |   |                     |    |   |   |   |   |   |   |   |   |   |
| Net (loss) income per share - basic                       |   | $                        | (0.76   | ) |   | $ | (1.02 | ) |   | $ | 0.31 |   |
| Weighted-average shares - basic                           |   |                     | 55,798  |   |   |   | 34,754 |   |   |   | 33,375 |   |
|                                                      |   |                     |    |   |   |   |   |   |   |   |   |   |
| Net (loss) income per share - diluted                     |   | $                        | (0.76   | ) |   | $ | (1.02 | ) |   | $ | 0.31 |   |
| Weighted-average shares - diluted                         |   |                     | 55,798  |   |   |   | 34,754 |   |   |   | 33,494 |   |

----

Table of Contents

|                                                     |   | Years Ended December 31, |    |
|----------------------------------------------------------|--------|--------------------------|---------|
|                                                     |   | 2013                     |    |   | 2012 |   |   | 2011 |   |
| Net (loss) income                                        |   | $                        | (42,572 | ) |   | $ | (35,431 | ) |   | $ | 10,381 |   |
| Other comprehensive income:                              |   |                     |    |   |   |   |   |   |   |   |   |   |
| Net change in unrealized loss on auction rate securities |   |                     | 68      |   |   |   | 8 |   |   |   | 24 |   |
| Total other comprehensive income                         |   |                     | 68      |   |   |   | 8 |   |   |   | 24 |   |
| Comprehensive (loss) income                              |   | $                        | (42,504 | ) |   | $ | (35,423 | ) |   | $ | 10,405 |   |

----

Table of Contents

|                                                                                                                         |   | Common Stock |   |   | Additional |   |   |                 |   |   | Accumulated Other   |   |   | Treasury Stock              |     |   |        |   |
|------------------------------------------------------------------------------------------------------------------------------|--------|--------------|--------|--------|------------|--------|--------|-----------------|--------|--------|---------------------|--------|--------|-----------------------------|----------|--------|--------|--------|
|                                                                                                                         |   | Shares       |   |   | Amount     |   |   | Paid-In Capital |   |   | Accumulated Deficit |   |   | Comprehensive Income (Loss) |     |   | Shares |   |   | Amount |   |   | Total |   |
| Balance at December 31, 2010                                                                                                 |   |         | 33,326 |   |       | $      | 43     |            |   | $      | 453,353             |   |   | $                           | (399,055 | )      |   | $      | (292 | ) |   |   | (200 | ) |   | $ | (2,741 | ) |   | $ | 51,308 |   |
| Net loss                                                                                                                     |   |         | -      |   |       |   | -      |            |   |   | -                   |   |   |                        | 10,381   |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 10,381 |   |
| Other comprehensive income                                                                                                   |   |         | -      |   |       |   | -      |            |   |   | -                   |   |   |                        | -        |   |   |   | 24 |   |   |   | - |   |   |   | - |   |   |   | 24 |   |
| Compensation expenses for share-based payment arrangements                                                                   |   |         | -      |   |       |   | -      |            |   |   | 6,362               |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 6,362 |   |
| Forfeitures of restricted stock                                                                                              |   |         | (38    | )      |       |   | -      |            |   |   | -                   |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Sale of common stock under employee stock purchase plans and exercise of stock options                                       |   |         | 758    |   |       |   | 1      |            |   |   | 3,725               |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 3,726 |   |
| Balance at December 31, 2011                                                                                                 |   |         | 34,046 |   |       |   | 44     |            |   |   | 463,440             |   |   |                        | (388,674 | )      |   |   | (268 | ) |   |   | (200 | ) |   |   | (2,741 | ) |   |   | 71,801 |   |
| Net income                                                                                                                   |   |         | -      |   |       |   | -      |            |   |   | -                   |   |   |                        | (35,431  | )      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (35,431 | ) |
| Other comprehensive income                                                                                                   |   |         | -      |   |       |   | -      |            |   |   | -                   |   |   |                        | -        |   |   |   | 8 |   |   |   | - |   |   |   | - |   |   |   | 8 |   |
| Compensation expenses for share-based payment arrangements                                                                   |   |         | -      |   |       |   | -      |            |   |   | 6,536               |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 6,536 |   |
| Sale of common stock in public offering, net of underwriting discounts and commissions ($1,518) and offering expenses ($434) |   |         | 12,650 |   |       |   | 17     |            |   |   | 23,331              |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 23,348 |   |
| Forfeitures of restricted stock                                                                                              |   |         | (6     | )      |       |   | -      |            |   |   | -                   |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Sale of common stock under employee stock purchase plans and exercise of stock options                                       |   |         | 75     |   |       |   | -      |            |   |   | 306                 |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 306 |   |
| Balance at December 31, 2012                                                                                                 |   |         | 46,765 |   |       |   | 61     |            |   |   | 493,613             |   |   |                        | (424,105 | )      |   |   | (260 | ) |   |   | (200 | ) |   |   | (2,741 | ) |   |   | 66,568 |   |
| Net loss                                                                                                                     |   |         | -      |   |       |   | -      |            |   |   | -                   |   |   |                        | (42,572  | )      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (42,572 | ) |
| Other comprehensive income                                                                                                   |   |         | -      |   |       |   | -      |            |   |   | -                   |   |   |                        | -        |   |   |   | 68 |   |   |   | - |   |   |   | - |   |   |   | 68 |   |
| Compensation expenses for share-based payment arrangements                                                                   |   |         | -      |   |       |   | -      |            |   |   | 3,546               |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 3,546 |   |
| Acquisition of subsidiary, net of issuance costs                                                                             |   |         | 4,472  |   |       |   | 6      |            |   |   | 11,214              |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 11,220 |   |
| Sale of common stock in public offering, net of underwriting discounts and commissions ($2,581) and offering expenses ($351) |   |         | 9,775  |   |       |   | 12     |            |   |   | 40,066              |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 40,078 |   |
| Forfeitures of restricted stock                                                                                              |   |         | (1     | )      |       |   | -      |            |   |   | -                   |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Exercise of stock options                                                                                                    |   |         | 14     |   |       |   | -      |            |   |   | 71                  |   |   |                        | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 71 |   |
| Balance at December 31, 2013                                                                                                 |   |         | 61,025 |   |       | $      | 79     |            |   | $      | 548,510             |   |   | $                           | (466,677 | )      |   | $      | (192 | ) |   |   | (200 | ) |   | $ | (2,741 | ) |   | $ | 78,979 |   |

----

Table of Contents

|                                                                                                               |   | Years Ended December 31, |    |
|--------------------------------------------------------------------------------------------------------------------|--------|--------------------------|---------|
|                                                                                                               |   | 2013                     |    |   | 2012 |   |   | 2011 |   |
| Cash flows from operating activities:                                                                              |   |                          |    |   |  |   |   |  |   |
| Net (loss) income                                                                                                  |   | $                        | (42,572 | ) |   | $ | (35,431 | ) |   | $ | 10,381 |   |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:                 |   |                     |    |   |   |   |   |   |   |   |   |   |
| Depreciation and amortization                                                                                      |   |                     | 939     |   |   |   | 1,324 |   |   |   | 2,066 |   |
| Losses (gains) on sales of fixed assets                                                                            |   |                     | 204     |   |   |   | (327 | ) |   |   | - |   |
| Intangible impairment charge                                                                                       |   |                     | 919     |   |   |   | - |   |   |   | - |   |
| Deferred income tax                                                                                                |   |                     | (362    | )  |   |   | - |   |   |   | - |   |
| Change in contingent consideration liability                                                                       |   |                     | (200    | )  |   |   | - |   |   |   | - |   |
| Expenses for share-based compensation awards                                                                       |   |                     | 3,546   |   |   |   | 6,536 |   |   |   | 6,362 |   |
| Changes in assets and liabilities:                                                                                 |   |                     |    |   |   |   |   |   |   |   |   |   |
| Decrease (increase) in accounts receivable                                                                         |   |                     | 4,114   |   |   |   | (5,421 | ) |   |   | 767 |   |
| Decrease (increase) in other current assets                                                                        |   |                     | 336     |   |   |   | (754 | ) |   |   | 882 |   |
| Decrease (increase) in deferred tax and other assets                                                               |   |                     | 2,044   |   |   |   | (2,002 | ) |   |   | 1,050 |   |
| (Decrease) in accounts payable and accrued expenses                                                                |   |                     | (1,956  | ) |   |   | (691 | ) |   |   | (3,352 | ) |
| (Decrease) increase in deferred revenue – current                                                            |   |                     | (886    | ) |   |   | 634 |   |   |   | 204 |   |
| (Decrease) increase in deferred tax and other current liabilities                                                  |   |                     | (2,069  | ) |   |   | 2,069 |   |   |   | 3 |   |
| (Decrease) increase in deferred revenue - long term                                                                |   |                     | -       |   |   |   | (162 | ) |   |   | 162 |   |
| (Decrease) in other liabilities                                                                                    |   |                     | (164    | ) |   |   | (419 | ) |   |   | (138 | ) |
| Net cash (used in) provided by operating activities                                                                |   |                     | (36,107 | ) |   |   | (34,644 | ) |   |   | 18,387 |   |
| Cash flows from investing activities:                                                                              |   |                     |    |   |   |   |   |   |   |   |   |   |
| Cash acquired in acquisition of subsidiary                                                                         |   |                     | 1,888   |   |   |   | - |   |   |   | - |   |
| Capital expenditures                                                                                               |   |                     | (137    | ) |   |   | (767 | ) |   |   | (226 | ) |
| Proceeds from sales of fixed assets                                                                                |   |                     | 174     |   |   |   | 390 |   |   |   | - |   |
| Proceeds from redemption of auction rate securities                                                                |   |                     | 1,100   |   |   |   | 100 |   |   |   | 300 |   |
| Net cash provided by (used in) investing activities                                                                |   |                     | 3,025   |   |   |   | (277 | ) |   |   | 74 |   |
| Cash flows from financing activities:                                                                              |   |                     |    |   |   |   |   |   |   |   |   |   |
| Equity issuance costs in connection with acquisition of subsidiary                                                 |   |                     | (45     | )  |   |   | - |   |   |   | - |   |
| Proceeds from public offering of common stock, net of underwriting discounts and commissions and offering expenses |   |                     | 40,078  |   |   |   | 23,348 |   |   |   | - |   |
| Proceeds from the exercise of stock options and sale of common stock under the employee stock purchase plans       |   |                     | 71      |   |   |   | 306 |   |   |   | 3,726 |   |
| Net cash provided by financing activities                                                                          |   |                     | 40,104  |   |   |   | 23,654 |   |   |   | 3,726 |   |
| Net increase (decrease) in cash and cash equivalents                                                               |   |                     | 7,022   |   |   |   | (11,267 | ) |   |   | 22,187 |   |
| Cash and cash equivalents at beginning of period                                                                   |   |                     | 58,838  |   |   |   | 70,105 |   |   |   | 47,918 |   |
| Cash and cash equivalents at end of period                                                                         |   | $                        | 65,860  |   |   | $ | 58,838 |   |   | $ | 70,105 |   |
|                                                                                                               |   |                     |    |   |   |   |   |   |   |   |   |   |
| Supplemental disclosure of cash flow information:                                                                  |   |                     |    |   |   |   |   |   |   |   |   |   |
| Contingent consideration liability                                                                                 |   | $                        | 15,700  |   |   | $ | - |   |   | $ | - |   |
| Stock acquisition consideration                                                                                    |   | $                        | 11,265  |   |   | $ | - |   |   | $ | - |   |

----

Table of Contents

----

Table of Contents

|                                                                  |   | Amount |    |
|-----------------------------------------------------------------------|--------|--------|---------|
| Consideration:                                                        |   |        |    |
| Progenics common stock consideration paid                             |   | $      | 11,265  |   |
| Contingent consideration (pursuant to future milestone obligations)   |   |   | 15,900  |   |
| Total consideration                                                   |   |   | 27,165  |   |
|                                                                  |   |   |    |   |
| Tangible assets acquired and liabilities assumed:                     |   |   |    |   |
| Cash and cash equivalents                                             |   |   | 1,888   |   |
| Accounts receivable                                                   |   |   | 56      |   |
| Other current assets                                                  |   |   | 529     |   |
| Fixed assets                                                          |   |   | 249     |   |
| Accounts payable, accrued expenses and deferred revenue - current     |   |   | (2,876  | ) |
| Deferred tax liability – long term                              |   |   | (12,683 | ) |
| Total tangible assets acquired and liabilities assumed                |   |   | (12,837 | ) |
|                                                                  |   |   |    |   |
| Intangible assets – in process research and development         |   |   | 32,300  |   |
| Total tangible and intangible assets acquired and liabilities assumed |   |   | 19,463  |   |
|                                                                  |   |   |    |   |
| Goodwill                                                              |   | $      | 7,702   |   |

----

Table of Contents

|                             |   | Three Months EndedDecember 31, |   |   | Year EndedDecember 31, |   |
|----------------------------------|--------|--------------------------------|--------|--------|------------------------|--------|
|                             |   | 2013                           |   |   | 2012                   |   |   | 2013 |   |   | 2012 |   |
| Revenues                         |   | $                              | 2,968  |   |                   | $      | 12,801 |   |   | $ | 7,867 |   |   | $ | 18,235 |   |
| Net loss                         |   |                           | (8,551 | )      |                   |   | (3,458 | ) |   |   | (43,736 | ) |   |   | (57,877 | ) |
| Basic and diluted loss per share |   |                           | (0.14  | )      |                   |   | (0.08 | ) |   |   | (0.78 | ) |   |   | (1.48 | ) |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                           |   | GrossAmount |   |   | AccumulatedAmortization |   |   | Net CarryingValue |   |
|--------------------------------|--------|-------------|--------|--------|-------------------------|--------|--------|-------------------|--------|
| Finite lived intangible assets |   | $           | 21     |   |                    | $      | 2      |              |   | $ | 19 |   |
| Total                          |   | $           | 21     |   |                    | $      | 2      |              |   | $ | 19 |   |

|                                       |   | Goodwill |   |   | IPR&D |   |
|--------------------------------------------|--------|----------|--------|--------|-----------|--------|
| Balance at January 1, 2013                 |   | $        | -      |   |      | $      | - |   |
| Increase related to MIP acquisition        |   |     | 7,702  |   |      |   | 32,300 |   |
| Reclassification to finite lived IPR&D |   |     | -      |   |      |   | (21 | ) |
| Impairment                                 |   |     | -      |   |      |   | (919 | ) |
| Balance at December 31, 2013               |   | $        | 7,702  |   |      | $      | 31,360 |   |

| ·  | Level 1 - Valuations based on unadjusted quoted market prices in active markets for identical securities.                                                                                                                                                     |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                                                                                                                                                                                          |
| ·  | Level 2 - Valuations based on observable inputs other than Level 1 prices, such as quoted prices for similar assets at the measurement date, quoted prices in markets that are not active or other inputs that are observable, either directly or indirectly. |
|         |                                                                                                                                                                                                                                                          |
| ·  | Level 3 - Valuations based on unobservable inputs that are significant to the overall fair value measurement, which as noted above involve management judgment.                                                                                               |

----

Table of Contents

| Computer equipment      | 3 years                                 |
|-------------------------|-----------------------------------------|
| Machinery and equipment | 5-7 years                               |
| Furniture and fixtures  | 5 years                                 |
| Leasehold improvements  | Earlier of life of improvement or lease |

----

Table of Contents

|                            |   | 2013   |   |   | 2012   |   |
|---------------------------------|--------|--------|--------|--------|--------|--------|
| Other current liabilities:      |   |        |   |   |        |   |
| Deferred lease incentive        |   | $      | 115    |   |   | $      | 115 |   |
| Total other current liabilities |   | $      | 115    |   |   | $      | 115 |   |
| Other liabilities:              |   |   |   |   |   |   |   |   |
| Deferred lease liability        |   | $      | 224    |   |   | $      | 273 |   |
| Deferred lease incentive        |   |   | 690    |   |   |   | 805 |   |
| Total other liabilities         |   | $      | 914    |   |   | $      | 1,078 |   |

----

Table of Contents

|                     |   |                             |   |   | Fair Value Measurements at December 31, 2013                  |   |
|--------------------------|--------|-----------------------------|--------|--------|---------------------------------------------------------------|--------|
|                     |   | Balance atDecember 31, 2013 |   |   | Quoted Prices in Active Markets for Identical Assets(Level 1) |   |   | Significant Other Observable Inputs(Level 2) |   |   | Significant Unobservable Inputs(Level 3) |   |
| Assets:                  |   |                             |   |   |                                                               |   |   |  |   |   |  |   |
| Money market funds       |   | $                           | 60,364 |   |                                                          | $      | 60,364 |   |   | $ | - |   |   | $ | - |   |
| Auction rate securities  |   |                        | 2,208  |   |                                                          |   | - |   |   |   | - |   |   |   | 2,208 |   |
| Total Assets             |   | $                           | 62,572 |   |                                                          | $      | 60,364 |   |   | $ | - |   |   | $ | 2,208 |   |
|                     |   |                        |   |   |                                                          |   |   |   |   |   |   |   |   |   |   |   |
| Liability:               |   |                        |   |   |                                                          |   |   |   |   |   |   |   |   |   |   |   |
| Contingent consideration |   | $                           | 15,700 |   |                                                          | $      | - |   |   | $ | - |   |   | $ | 15,700 |   |
| Total Liability          |   | $                           | 15,700 |   |                                                          | $      | - |   |   | $ | - |   |   | $ | 15,700 |   |

|                    |   |                             |   |   | Fair Value Measurements at December 31, 2012                  |   |
|-------------------------|--------|-----------------------------|--------|--------|---------------------------------------------------------------|--------|
|                    |   | Balance atDecember 31, 2012 |   |   | Quoted Prices in Active Markets for Identical Assets(Level 1) |   |   | Significant Other Observable Inputs(Level 2) |   |   | Significant Unobservable Inputs(Level 3) |   |
|                    |   |                             |   |   |                                                               |   |   |  |   |   |  |   |
| Money market funds      |   | $                           | 56,224 |   |                                                          | $      | 56,224 |   |   | $ | - |   |   | $ | - |   |
| Auction rate securities |   |                        | 3,240  |   |                                                          |   | - |   |   |   | - |   |   |   | 3,240 |   |
| Total                   |   | $                           | 59,464 |   |                                                          | $      | 56,224 |   |   | $ | - |   |   | $ | 3,240 |   |

----

Table of Contents

----

Table of Contents

|                               |   | Fair Valueas ofDecember 31, 2013 |   | Valuation Technique |                                                 | Unobservable Input |                                     | Range(Weighted Average) |                   |
|------------------------------------|--------|----------------------------------|--------|---------------------|-------------------------------------------------|--------------------|------------------------------------------|-------------------------|------------------------|
|                               |   |                                  |   |                |                                                 |               |                                     |                         |                   |
| Asset:                             |   |                                  |   |                |                                                 |               |                                     |                         |                   |
| Auction Rate Securities            |   | $                                | 2,208  |                | Discounted cash flow model                      |                    | Redemption period                        |                    | 5 to 15 years(6 years) |   |
|                               |   |                             |   |                |                                  |                    | Discount rate                            |                    |                   | 0.25% - 3.00% (1.55%) |   |
| Contingent considerationliability: |   |                             |   |                |                                            |                    |                                     |                    |                   |   |   |
|                               |   |                             |   |                |                                            |                    |                                     |                    |                   |   |   |
| Azedra commercialization           |   | $                                | 2,300  |                | Probability adjusted discounted cash flow model |                    | Probability of success                   |                    |                   | 40% |   |
|                               |   |                             |   |                |                                  |                    | Period of milestone expected achievement |                    |                   | 2017 |   |
|                               |   |                             |   |                |                                  |                    | Discount rate                            |                    |                   | 10% |   |
|                               |   |                             |   |                |                                            |                    |                                     |                    |                   |   |   |
| 1404 commercialization             |   | $                                | 2,000  |                | Probability adjusted discounted cash flow model |                    | Probability of success                   |                    |                   | 31% |   |
|                               |   |                             |   |                |                                  |                    | Period of milestone expected achievement |                    |                   | 2018 |   |
|                               |   |                             |   |                |                                  |                    | Discount rate                            |                    |                   | 10% |   |
|                               |   |                             |   |                |                                            |                    |                                     |                    |                   |   |   |
| MIP-1095 commercialization         |   | $                                | 500    |                | Probability adjusted discounted cash flow model |                    | Probability of success                   |                    |                   | 19% |   |
|                               |   |                             |   |                |                                  |                    | Period of milestone expected achievement |                    |                   | 2021 |   |
|                               |   |                             |   |                |                                  |                    | Discount rate                            |                    |                   | 10% |   |
|                               |   |                             |   |                |                                            |                    |                                     |                    |                   |   |   |
| Net sales targets                  |   | $                                | 10,900 |                | Monte-Carlo simulation                          |                    | Probability of success                   |                    |                   | 19% - 40%(32.8%) |   |
|                               |   |                             |   |                |                                  |                    | Period of milestone expected achievement |                    |                   | 2018 - 2022 |   |
|                               |   |                             |   |                |                                  |                    | Discount rate                            |                    |                   | 12.5% |   |

|                    |   | Fair Value as of December 31, 2012 |   | Valuation Technique |                            | Unobservable Input |              | Range (Weighted Average) |                     |
|-------------------------|--------|------------------------------------|--------|---------------------|----------------------------|--------------------|-------------------|--------------------------|--------------------------|
|                    |   |                                    |   |                |                            |               |              |                          |                     |
| Asset:                  |   |                                    |   |                |                            |               |              |                          |                     |
| Auction Rate Securities |   | $                                  | 3,240  |                | Discounted cash flow model |                    | Redemption period |                     | 4 to 15 years(5.9 years) |   |
|                    |   |                               |   |                |             |                    | Discount rate     |                     |                     | 0.125% - 2.102% (0.71%) |   |

----

Table of Contents

|                                                                                                                                                                                             |   | Asset – Auction Rate SecuritiesFair Value Measurements Using SignificantUnobservable Inputs(Level 3) |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------|--------|
| Description                                                                                                                                                                                      |   | 2013                                                                                                       |   |   | 2012 |   |
| Balance at beginning of period                                                                                                                                                                   |   | $                                                                                                          | 3,240  |   |   | $ | 3,332 |   |
| Transfers into Level 3                                                                                                                                                                           |   |                                                                                                       | -      |   |   |   | - |   |
| Total realized/unrealized gains (losses)                                                                                                                                                         |   |                                                                                                       |   |   |   |   |   |   |
| Included in net income (loss)                                                                                                                                                                    |   |                                                                                                       | -      |   |   |   | - |   |
| Included in comprehensive income (loss)                                                                                                                                                          |   |                                                                                                       | 68     |   |   |   | 8 |   |
| Settlements                                                                                                                                                                                      |   |                                                                                                       | (1,100 | ) |   |   | (100 | ) |
| Balance at end of period                                                                                                                                                                         |   | $                                                                                                          | 2,208  |   |   | $ | 3,240 |   |
| Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date |   | $                                                                                                          | -      |   |   | $ | - |   |

|                                                                                                                                                         |   | Liability – Contingent ConsiderationFair Value Measurements Using SignificantUnobservable Inputs(Level 3) |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------|--------|
| Description                                                                                                                                                  |   | 2013                                                                                                            |   |   | 2012 |   |
| Balance at beginning of period                                                                                                                               |   | $                                                                                                               | -      |   |   | $ | - |   |
| Fair value of contingent consideration – acquisition of Molecular Insight                                                                              |   |                                                                                                            | 15,900 |   |   |   | - |   |
| Fair value adjustment to contingent consideration included in net loss                                                                                       |   |                                                                                                            | (200   | ) |   |   | - |   |
| Balance at end of period                                                                                                                                     |   | $                                                                                                               | 15,700 |   |   | $ | - |   |
| Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period |   | $                                                                                                               | (200   | ) |   | $ | - |   |

|                               |   | Amortized  |   |   | Fair   |   |   | Unrealized Holding |   |
|------------------------------------|--------|------------|--------|--------|--------|--------|--------|--------------------|--------|
| 2013:                              |   | Cost Basis |   |   | Value  |   |   | Gains              |   |   | (Losses) |   |   | Net |   |
| Maturities greater than ten years: |   |            |   |   |        |   |   |                    |   |   |  |   |   |  |   |
| Auction rate securities            |   | $          | 2,400  |   |   | $      | 2,208  |               |   | $ | - |   |   | $ | (192 | ) |   | $ | (192 | ) |
|                               |   | $          | 2,400  |   |   | $      | 2,208  |               |   | $ | - |   |   | $ | (192 | ) |   | $ | (192 | ) |

|                                       |   | Amortized  |   |   | Fair   |   |   | Unrealized Holding |   |
|--------------------------------------------|--------|------------|--------|--------|--------|--------|--------|--------------------|--------|
| 2012:                                      |   | Cost Basis |   |   | Value  |   |   | Gains              |   |   | (Losses) |   |   | Net |   |
| Maturities greater than ten years:         |   |            |   |   |        |   |   |                    |   |   |  |   |   |  |   |
| Auction rate securities                    |   | $          | 2,500  |   |   | $      | 2,300  |               |   | $ | - |   |   | $ | (200 | ) |   | $ | (200 | ) |
| Investments without stated maturity dates: |   |       |   |   |   |   |   |               |   |   |   |   |   |   |   |   |   |   |   |   |
| Auction rate securities                    |   |       | 1,000  |   |   |   | 940    |               |   |   | - |   |   |   | (60 | ) |   |   | (60 | ) |
|                                       |   | $          | 3,500  |   |   | $      | 3,240  |               |   | $ | - |   |   | $ | (260 | ) |   | $ | (260 | ) |

----

Table of Contents

| 2013:                     |   | Less than 12 Months |   |   | 12 Months or Greater |   |   | Total      |   |
|---------------------------|--------|---------------------|--------|--------|----------------------|--------|--------|------------|--------|
| Description of Securities |   | Fair Value          |   |   | Unrealized Losses    |   |   | Fair Value |   |   | Unrealized Losses |   |   | Fair Value |   |   | Unrealized Losses |   |
|                      |   |                     |   |   |                      |   |   |            |   |   |  |   |   |  |   |   |  |   |
| Auction rate securities   |   | $                   | -      |   |                 | $      | -      |       |   | $ | 2,208 |   |   | $ | (192 | ) |   | $ | 2,208 |   |   | $ | (192 | ) |
| Total                     |   | $                   | -      |   |                 | $      | -      |       |   | $ | 2,208 |   |   | $ | (192 | ) |   | $ | 2,208 |   |   | $ | (192 | ) |

| 2012:                     |   | Less than 12 Months |   |   | 12 Months or Greater |   |   | Total      |   |
|---------------------------|--------|---------------------|--------|--------|----------------------|--------|--------|------------|--------|
| Description of Securities |   | Fair Value          |   |   | Unrealized Losses    |   |   | Fair Value |   |   | Unrealized Losses |   |   | Fair Value |   |   | Unrealized Losses |   |
|                      |   |                     |   |   |                      |   |   |            |   |   |  |   |   |  |   |   |  |   |
| Auction rate securities   |   | $                   | -      |   |                 | $      | -      |       |   | $ | 3,240 |   |   | $ | (260 | ) |   | $ | 3,240 |   |   | $ | (260 | ) |
| Total                     |   | $                   | -      |   |                 | $      | -      |       |   | $ | 3,240 |   |   | $ | (260 | ) |   | $ | 3,240 |   |   | $ | (260 | ) |

|                                  |   | 2013   |   |   | 2012   |   |
|---------------------------------------|--------|--------|--------|--------|--------|--------|
| Collaborators                         |   | $      | 12     |   |   | $      | 6,125 |   |
| Royalties                             |   |   | 2,862  |   |   |   | 781 |   |
| Research grants                       |   |   | -      |   |   |   | 12 |   |
| Other                                 |   |   | 12     |   |   |   | 19 |   |
|                                  |   |   | 2,886  |   |   |   | 6,937 |   |
| Less, allowance for doubtful accounts |   |   | (7     | )      |   |   | - |   |
| Total                                 |   | $      | 2,879  |   |   | $      | 6,937 |   |

----

Table of Contents

|                                            |   | 2013   |    |   | 2012   |   |
|-------------------------------------------------|--------|--------|---------|--------|--------|--------|
| Computer equipment                              |   | $      | 2,234   |   |   | $      | 2,166 |   |
| Machinery and equipment                         |   |   | 7,091   |   |   |   | 8,031 |   |
| Furniture and fixtures                          |   |   | 170     |   |   |   | 133 |   |
| Leasehold improvements                          |   |   | 5,020   |   |   |   | 5,327 |   |
| Other                                           |   |   | 16      |   |   |   | 12 |   |
|                                            |   |   | 14,531  |   |   |   | 15,669 |   |
| Less, accumulated depreciation and amortization |   |   | (12,118 | )      |   |   | (12,270 | ) |
| Total                                           |   | $      | 2,413   |   |   | $      | 3,399 |   |

|                                        |   | 2013   |   |   | 2012   |   |
|---------------------------------------------|--------|--------|--------|--------|--------|--------|
| Accrued consulting and clinical trial costs |   | $      | 2,672  |   |   | $      | 2,193 |   |
| Accrued payroll and related costs           |   |   | 2,123  |   |   |   | 1,552 |   |
| Restructuring accrual                       |   |   | -      |   |   |   | 813 |   |
| Legal and professional fees                 |   |   | 608    |   |   |   | 774 |   |
| Accounts payable                            |   |   | 793    |   |   |   | 229 |   |
| Other                                       |   |   | 316    |   |   |   | 79 |   |
| Total                                       |   | $      | 6,512  |   |   | $      | 5,640 |   |

----

Table of Contents

|                         |   | Severance and Related Benefits |   |   | Other Exit Costs |   |   | Contract Termination Costs |   |   | Total Restructuring Accrual |   |
|------------------------------|--------|--------------------------------|--------|--------|------------------|--------|--------|----------------------------|--------|--------|-----------------------------|--------|
| Balance at December 31, 2010 |   | $                              | -      |   |             | $      | -      |                       |   | $      | -                           |   |   | $ | - |   |
|  Additions, net         |   |                           | 1,341  |   |             |   | 8      |                       |   |   | 292                         |   |   |   | 1,641 |   |
| Payments                     |   |                           | (770   | )      |             |   | (2     | )                          |   |   | (138                        | )      |   |   | (910 | ) |
| Balance at December 31, 2011 |   |                           | 571    |   |             |   | 6      |                       |   |   | 154                         |   |   |   | 731 |   |
| Additions, net               |   |                           | 1,905  |   |             |   | 184    |                       |   |   | 3                           |   |   |   | 2,092 |   |
| Payments                     |   |                           | (1,663 | )      |             |   | (190   | )                          |   |   | (157                        | )      |   |   | (2,010 | ) |
| Balance at December 31, 2012 |   |                           | 813    |   |             |   | -      |                       |   |   | -                           |   |   |   | 813 |   |
| Additions, net               |   |                           | 1,492  |   |             |   | 15     |                       |   |   | 1,359                       |   |   |   | 2,866 |   |
| Payments                     |   |                           | (2,305 | )      |             |   | (15    | )                          |   |   | (1,359                      | )      |   |   | (3,679 | ) |
| Balance at December 31, 2013 |   | $                              | -      |   |             | $      | -      |                       |   | $      | -                           |   |   | $ | - |   |

| Years ending December 31, |   | MinimumAnnual Payments |   |
|---------------------------|--------|------------------------|--------|
| 2014                      |   | $                      | 1,841  |   |
| 2015                      |   |                   | 1,887  |   |
| 2016                      |   |                   | 1,934  |   |
| 2017                      |   |                   | 1,983  |   |
| 2018                      |   |                   | 2,032  |   |
| Thereafter                |   |                   | 4,218  |   |
| Total                     |   | $                      | 13,895 |   |

----

Table of Contents

|                                                 |   | Paid from inception to December 31, 2013        |   |   | Future (1)Commitments |   | Terms  |
|------------------------------------------------------|--------|-------------------------------------------------|--------|--------|-----------------------|--------|--------|
| Progenics agreements with:                           |
| Lonza Sales AG                                       |   | $                                               | 909    |   |                  | $      | 824    |   | Annual license fee payments, milestones and royalties, as applicable, in respect of oncology and other products. |
|                                                 |   |                                            |   |   |                  |   |   |   |      |
| PSMA LLC agreements with:                            |
| Seattle Genetics, Inc.                               |   |                                            | 4,400  |   |                  |   | 13,900 |   | Milestone and periodic maintenance payments to use ADC technology to link chemotherapeutic agents to monoclonal antibodies that target prostate specific membrane antigen. ADC technology is based in part on technology licensed by SGI from third parties. |
| Amgen Fremont, Inc. (formerly Abgenix)               |   |                                            | 1,350  |   |                  |   | 5,750  |   | Milestones and royalties to use XenoMouse® technology for generating fully human antibodies to PSMA LLC's PSMA antigen. |
| Former member of PSMA LLC                            |   |                                            | 278    |   |                  |   | 52,188 |   | Annual minimum royalty payments and milestones to use technology related to PSMA. |
|                                                 |   |                                            |   |   |                  |   |   |   |      |
|                                                 |   | Paid from acquisition date to December 31, 2013 |   |   | Future (1)Commitments |   | Terms  |
| MIP agreements with:                                 |   |                                            |   |   |                  |   |   |   |     |
|                                                 |   |                                            |   |   |                  |   |   |   |      |
| University of Zurich and the Paul Scherrer Institute |   |                                            | 65     |   |                  |   | 1,225  |   | Annual maintenance and license fee payments, milestones and royalties in respect of licensed technology related to 1404. |
| University of Western Ontario                        |   |                                            | 4      |   |                  |   | 374    |   | Annual minimum royalty, administration and milestone payments in respect of licensed technology related to Azedra. |
| Novartis Pharma AG and other interests               |   |                                            | -      |   |                  |   | 4,600  |   | Milestone and royalty payments in respect of licensed technology related to Onalta. |
| Bayer Schering Pharma AG                             |   |                                            | -      |   |                  |   | 9,000  |   | Milestone and royalty payments in respect of licensed technology related to a MIP asset. |
|                                                 |   |                                            |   |   |                  |   |   |   |      |

----

Table of Contents

----

Table of Contents

|                                   |   | 2013   |               |   | 2012   |   |               | 2011   |   |
|----------------------------------------|--------|--------|--------------------|--------|--------|--------|--------------------|--------|--------|
|                                   |   |        |               |   |        |   |               |        |   |
| Expected volatility                    |   |   | 73% – 90     | %      |   |   | 70% – 85     | %      |   |   | 68% – 78 | % |
| Expected dividends                     |   | Zero   |               |   | Zero   |   |               | Zero   |   |
| Expected term (years)                  |   |   | 5.3 – 10     |   |   |   | 5.3 – 10     |   |   |   | 5.3 – 10 |   |
| Weighted average expected term (years) |   |   | 5.96               |   |   |   | 6.11               |   |   |   | 6.17 |   |
| Risk-free rate                         |   |   | 0.76% – 2.83 | %      |   |   | 0.57% – 1.71 | %      |   |   | 0.77% – 2.97 | % |

| Options                          |   | Shares |   |   | Weighted Average Exercise Price |   |   | Weighted Average Remaining Contractual Term (Yr.) |   |   | Aggregate Intrinsic Value |   |
|----------------------------------|--------|--------|--------|--------|---------------------------------|--------|--------|---------------------------------------------------|--------|--------|---------------------------|--------|
|                             |   |        |   |   |                                 |   |   |                                                   |   |   |                           |   |
| Outstanding at January 1, 2013   |   |   | 5,366  |   |                            | $      | 12.27  |                                              |   |        |                      |   |  |   |
| Granted                          |   |   | 1,018  |   |                            |   | 5.13   |                                              |   |        |                      |   |  |   |
| Exercised                        |   |   | (14    | )      |                            |   | 5.08   |                                              |   |        |                      |   |  |   |
| Forfeited                        |   |   | (608   | )      |                            |   | 10.63  |                                              |   |        |                      |   |  |   |
| Expired                          |   |   | (463   | )      |                            |   | 14.70  |                                              |   |        |                      |   |  |   |
| Outstanding at December 31, 2013 |   |   | 5,299  |   |                            |   | 10.89  |                                              |   |   | 5.82                      |   |   | $ | 304 |   |
| Exercisable at December 31, 2013 |   |   | 3,875  |   |                            | $      | 12.45  |                                              |   |   | 4.86                      |   |   | $ | 118 |   |

----

Table of Contents

| Restricted Stock Awards        |   | Shares |   |   | Weighted Average Grant-DateFair Value |   |
|--------------------------------|--------|--------|--------|--------|---------------------------------------|--------|
|                           |   |        |   |   |                                       |   |
| Nonvested at January 1, 2013   |   |   | 28     |   |                                  | $      | 5.35 |   |
| Granted                        |   |   | -      |   |                                  |   | - |   |
| Vested                         |   |   | (27    | )      |                                  |   | 5.35 |   |
| Forfeited                      |   |   | (1     | )      |                                  |   | 5.35 |   |
| Nonvested at December 31, 2013 |   |   | -      |   |                                  | $      | - |   |

|                |   | 2011     |               |
|---------------------|--------|----------|--------------------|
|                |   |          |               |
| Expected volatility |   |     | 43% – 51     | % |
| Expected dividends  |   | zero     |               |
| Expected term       |   | 6 months |               |
| Risk-free rate      |   |     | 0.06% – 0.22 | % |

----

Table of Contents

|   |   | Qualified Plan   |   |   | Non-Qualified Plan |   |
|--------|--------|------------------|--------|--------|--------------------|--------|
|   |   | Shares Purchased |   |   | Price Range        |   |   | WeightedAverage Grant-Date Fair Value |   |   | Shares Purchased |   |   | Price Range |   |   | WeightedAverage Grant-Date Fair Value |   |
|   |   |                  |   |   |                    |   |   |  |   |   |  |   |   |  |   |   |  |   |
| 2011   |   |             | 428    |   |               | $      | 4.62 – $5.65 |   |   | $ | 0.88 |   |   |   | 162 |   |   | $ | 4.62 – $5.65 |   |   | $ | 0.84 |   |

|                       |   | 2013   |   |   | 2012   |   |   | 2011   |   |
|----------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Recognized as:             |   |        |   |   |        |   |   |        |   |
| Research and Development   |   | $      | 2,524  |   |   | $      | 4,568  |   |   | $ | 4,499 |   |
| General and Administrative |   |   | 1,022  |   |   |   | 1,968  |   |   |   | 1,863 |   |
| Total                      |   | $      | 3,546  |   |   | $      | 6,536  |   |   | $ | 6,362 |   |

----

Table of Contents

|                                              |   | 2013   |     |   | 2012   |   |
|---------------------------------------------------|--------|--------|----------|--------|--------|--------|
| Deferred tax assets:                              |   |        |     |   |        |   |
| Depreciation and amortization                     |   | $      | 6,165    |   |   | $      | 6,497 |   |
| R&E tax credit carry-forwards                 |   |   | 5,129    |   |   |   | 11,843 |   |
| NYS investment tax credit carry-forwards          |   |   | 1,095    |   |   |   | 1,084 |   |
| AMT credit carry-forwards                         |   |   | 211      |   |   |   | 211 |   |
| Net operating loss carry-forwards                 |   |   | 190,263  |   |   |   | 112,966 |   |
| Capitalized research and development expenditures |   |   | 25,231   |   |   |   | 30,884 |   |
| Stock compensation                                |   |   | 13,826   |   |   |   | 14,436 |   |
| Other items                                       |   |   | 1,097    |   |   |   | 2,193 |   |
| Total gross deferred tax assets                   |   |   | 243,017  |   |   |   | 180,114 |   |
| Less: Valuation allowance                         |   |   | (243,017 | )      |   |   | (178,045 | ) |
| Deferred tax assets                               |   |   | -        |   |   |   | 2,069 |   |
| Deferred tax liability - current                  |   |   | -        |   |   |   | (2,069 | ) |
| Deferred tax liability – long term          |   |   | (12,321  | )      |   |   | - |   |
| Net deferred tax liability                        |   | $      | (12,321  | )      |   | $      | - |   |

----

Table of Contents

|                                                             |   | 2013   |   |   | 2012   |   |   | 2011   |   |
|------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
|                                                             |   |        |   |   |        |   |   |        |   |
| U.S. Federal statutory rate                                      |   |   | (34.0  | )%     |   |   | (35.0  | )%     |   |   | 35.0 | % |
| State income taxes, net of Federal benefit                       |   |   | (4.9   | )      |   |   | (5.4   | )      |   |   | 8.0 |   |
| Research and experimental tax credit                             |   |   | (3.6   | )      |   |   | -      |   |   |   | (4.1 | ) |
| Change in valuation allowance                                    |   |   | 11.4   |   |   |   | 34.7   |   |   |   | (22.6 | ) |
| Effect of federal tax rate bracket change on valuation allowance |   |   | 8.7    |   |   |   | -      |   |   |   | (34.8 | ) |
| Equity compensation                                              |   |   | 3.1    |   |   |   | 4.2    |   |   |   | 17.0 |   |
| Investment tax credit                                            |   |   | (0.1   | )      |   |   | -      |   |   |   | (0.1 | ) |
| NOL expiration – Section 382                               |   |   | 18.6   |   |   |   | -      |   |   |   | - |   |
| Other                                                            |   |   | -      |   |   |   | 1.5    |   |   |   | 1.6 |   |
| Income tax provision (benefit)                                   |   |   | (0.8   | )%     |   |   | 0.0    | %      |   |   | 0.0 | % |

----

Table of Contents

|                             |   | 2013   |
|----------------------------------|--------|--------|
|                             |   |        |
| Beginning uncertain tax benefits |   | $      | 2,661 |
| Current year - increases         |   |   | - |
| Current year - decreases         |   |   | - |
| Settlements                      |   |   | - |
| Expired statuses                 |   |   | - |
| Ending uncertain tax benefits    |   | $      | 2,661 |

|                                            |   | Net (Loss) Income (Numerator) |    |   | Weighted AverageCommon Shares (Denominator) |   |   | Per Share Amount |   |
|-------------------------------------------------|--------|-------------------------------|---------|--------|---------------------------------------------|--------|--------|------------------|--------|
| 2013:                                           |   |                               |    |   |                                             |   |   |                  |   |
| Basic and diluted                               |   | $                             | (42,572 | )      |                                        |   | 55,798 |             |   | $ | (0.76 | ) |
| 2012:                                           |   |                          |    |   |                                        |   |   |             |   |   |   |   |
| Basic and diluted                               |   | $                             | (35,431 | )      |                                        |   | 34,754 |             |   | $ | (1.02 | ) |
| 2011:                                           |   |                          |    |   |                                        |   |   |             |   |   |   |   |
| Basic                                           |   | $                             | 10,381  |   |                                        |   | 33,375 |             |   | $ | 0.31 |   |
|   Dilutive effect of stock options    |   |                          | -       |   |                                        |   | 66     |             |   |   |   |   |
|   Dilutive effect of restricted stock |   |                          | -       |   |                                        |   | 53     |             |   |   |   |   |
| Diluted                                         |   | $                             | 10,381  |   |                                        |   | 33,494 |             |   | $ | 0.31 |   |

----

Table of Contents

|             |   | 2013                   |   |   | 2012                           |   |   | 2011                   |
|------------------|--------|------------------------|--------|--------|--------------------------------|--------|--------|------------------------|
|             |   | WeightedAverage Number |   |   | WeightedAverage Exercise Price |   |   | WeightedAverage Number |   |   | WeightedAverage Exercise Price |   |   | WeightedAverage Number |   |   | WeightedAverage Exercise Price |
| Options          |   |                   | 5,969  |   |                           | $      | 11.54  |                   |   |   | 5,947 |   |   | $ | 12.32 |   |   |   | 4,543 |   |   | $ | 14.92 |
| Restricted stock |   |                   | -      |   |                           |   |   |                   |   |   | 60 |   |   |   |   |   |   |   | 45 |   |   |   |   |
| Total            |   |                   | 5,969  |   |                           |   |   |                   |   |   | 6,007 |   |   |   |   |   |   |   | 4,588 |   |   |   |   |

|                                   |   | 2013 Quarter Ended |    |
|----------------------------------------|--------|--------------------|---------|
|                                   |   | March 31           |    |   | June 30 |   |   | September 30 |   |   | December 31 |   |
| Revenues                               |   | $                  | 2,226   |   |   | $ | 1,801 |   |   | $ | 867 |   |   | $ | 2,968 |   |
| Net loss                               |   |               | (11,258 | ) |   |   | (12,263 | ) |   |   | (10,500 | ) |   |   | (8,551 | ) |
| Net loss per share - basic and diluted |   |               | (0.22   | ) |   |   | (0.24 | ) |   |   | (0.17 | ) |   |   | (0.14 | ) |

|                                   |   | 2012 Quarter Ended |    |
|----------------------------------------|--------|--------------------|---------|
|                                   |   | March 31           |    |   | June 30 |   |   | September 30 |   |   | December 31 |   |
| Revenues (1)                           |   | $                  | 2,226   |   |   | $ | 1,820 |   |   | $ | 1,117 |   |   | $ | 8,885 |   |
| Net loss                               |   |               | (13,086 | ) |   |   | (10,720 | ) |   |   | (11,301 | ) |   |   | (324 | ) |
| Net loss per share - basic and diluted |   |               | (0.39   | ) |   |   | (0.32 | ) |   |   | (0.33 | ) |   |   | (0.01 | ) |

| (1) | Revenues in the fourth quarter of 2012 include $5.0 million and $2.8 million from the MedImmune and CytoDyn Agreements, respectively. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Year ended December 31, |   | Beginning Balance |   |   | AdditionsCharged to General and administrative expenses |   |   | DeductionsAccounts Written Off During Period |   |   | Ending Balance |   |
|-------------------------|--------|-------------------|--------|--------|---------------------------------------------------------|--------|--------|----------------------------------------------|--------|--------|----------------|--------|
| (in thousands)          |   |                   |   |   |                                                         |   |   |                                              |   |   |                |   |
| 2013                    |   | $                 | -      |   |                                                    | $      | 7      |                                         |   | $      | -              |   |   | $ | 7 |   |

----

Table of Contents

|   | PROGENICS PHARMACEUTICALS, INC. |
|--------|---------------------------------|
|   | By:                             | /s/ MARK R. BAKER |
|   |                            | Mark R. Baker Chief Executive Officer and Director(Principal Executive Officer) |

| Signature                        |   | Capacity                                     | Date           |
|----------------------------------|--------|----------------------------------------------|----------------|
|  /s/ PETER J. CROWLEY       |   | Chairman                                     | March 13, 2014 |
| Peter J. Crowley                 |   |                                         |           |
|                             |        |                                              |                |
| /s/ PAUL J. MADDON               |   | Vice Chairman                                | March 13, 2014 |
| Paul J. Maddon, M.D., Ph.D.      |   |                                         |           |
|                             |        |                                              |                |
| /s/ MARK R. BAKER                |   | Chief Executive Officer and Director         | March 13, 2014 |
| Mark R. Baker                    |   | (Principal Executive Officer)                |           |
|                             |   |                                         |           |
| /s/ KAREN J. FERRANTE            |   | Director                                     | March 13, 2014 |
| Karen J. Ferrante, M.D.          |   |                                         |           |
|                             |        |                                              |                |
| /s/ MICHAEL D. KISHBAUCH         |   | Director                                     | March 13, 2014 |
| Michael D. Kishbauch             |   |                                         |           |
|                             |        |                                              |                |
| /s/ DAVID A. SCHEINBERG          |   | Director                                     | March 13, 2014 |
| David A. Scheinberg, M.D., Ph.D. |   |                                         |           |
|                             |        |                                              |                |
| /s/ NICOLE S. WILLIAMS           |   | Director                                     | March 13, 2014 |
| Nicole S. Williams               |   |                                         |           |
|                             |        |                                              |                |
| /s/ ANGELO W. LOVALLO, JR.       |   | Vice President, Finance and Treasurer        | March 13, 2014 |
| Angelo W. Lovallo, Jr.           |   | (Principal Financial and Accounting Officer) |           |
|                             |   |                                         |           |

----

Table of Contents

|              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Exhibit           |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Number *          |   | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 3.1(1)            |   | Amended and Restated Certificate of Incorporation of the Registrant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 3.2(2)            |   | Amended and Restated By-laws of the Registrant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 4.1(3)            |   | Specimen Certificate for Common Stock, $0.0013 par value per share, of the Registrant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 10.5(4)           |   | Amended and Restated 1996 Stock Incentive Plan‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 10.6.3(5)         |   | Amended 2005 Stock Incentive Plan ‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 10.6.4(6)         |   | Form of Non-Qualified Stock Option Award Agreement ‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 10.6.5(6)         |   | Form of Restricted Stock Award Agreement ‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 10.7(7)           |   | Form of Indemnification Agreement‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 10.8.2(8)         |   | Retirement Agreement, dated as of March 14, 2012, between the Registrant and Dr. Paul J. Maddon‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 10.9(3)           |   | Letter dated August 25, 1994 between the Registrant and Dr. Robert J. Israel‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 10.16(9)†   |   | Development and License Agreement, dated April 30, 1999, between Protein Design Labs, Inc. and the Registrant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 10.16.1(10)       |   | Letter Agreement, dated November 24, 2003, relating to the Development and License Agreement between Protein Design Labs, Inc. and the Registrant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.19(11)†  |   | Exclusive Sublicense Agreement, dated September 21, 2001, between the Registrant and UR Labs, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.19.1(12)       |   | Amendment to Exclusive Sublicense Agreement, dated September 21, 2001, between the Registrant and UR Labs, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 10.21.1(13)       |   | Amended and Restated Agreement of Lease, dated October 28, 2009, between BMR-Landmark at Eastview LLC and the Registrant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 10.23             |   | Information concerning compensation of the Registrant's non-employee directors is included in the Registrant's proxy material for its 2013 Annual Meeting of Stockholders and its Current Report on Form 8-K filed onSeptember 12, 2013 and is incorporated herein by reference.‡                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.25(14) † |   | Option and License Agreement, dated May 8, 1985, by and between the University of Chicago and UR Labs, Inc., as amended by (i) Amendment to Option and License Agreement, dated September 17, 1987, by and between the University of Chicago and UR Labs, Inc., (ii) Second Amendment to Option and License Agreement, dated March 3, 1989, by and among the University of Chicago, ARCH Development Corporation and UR Labs, Inc., and (iii) Letter Agreement Related to Progenics' Relistor In-License dated, December 22, 2005, by and among the University of Chicago, acting on behalf of itself and ARCH Development Corporation, the Registrant, Progenics Pharmaceuticals Nevada, Inc. and Wyeth, acting through its Wyeth Pharmaceuticals Division. |
| 10.26(15)         |   | Membership Interest Purchase Agreement, dated April 20, 2006, between the Registrant Inc. and Cytogen Corporation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.27(15) † |   | Amended and Restated PSMA/PSMP License Agreement, dated April 20, 2006, by and among the Registrant, Cytogen Corporation and PSMA Development Company LLC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 10.29(16) † |   | License Agreement, dated as of October 16, 2008, by and among Ono Pharmaceutical Co., Ltd. and the Registrant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 10.30(16) † |   | Partial Termination and License Agreement, dated October 16, 2008, by and among Wyeth, acting through Wyeth Pharmaceuticals Division, Wyeth-Whitehall Pharmaceuticals, Inc. and Wyeth-Ayerst Lederle, Inc. and the Registrant and Progenics Pharmaceuticals Nevada, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 10.31(16) † |   | Consent, Acknowledgment and Agreement, dated as of October 16, 2008, by and among Wyeth, acting through Wyeth Pharmaceuticals Division, Wyeth-Whitehall Pharmaceuticals, Inc. and Wyeth-Ayerst Lederle, Inc., the Registrant and Ono Pharmaceutical Co., Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 10.32(16) † |   | 2008 Agreement Related to Progenics' MNTX In-License, dated October 16, 2008, by and among the University of Chicago, acting on behalf of itself and ARCH Development Corporation, the Registrant, Progenics Pharmaceuticals Nevada, Inc. and Ono Pharmaceutical Co., Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

----

Table of Contents

|                 |   |                                                                                                                                                                                                                                                                      |
|----------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.34(17) †    |   | Collaboration Agreement, effective June 14, 2005, by and between Seattle Genetics, Inc. and PSMA Development Company, LLC.                                                                                                                                                |
| 10.37(9) †     |   | License Agreement dated as of February 3, 2011, by and between Salix Pharmaceuticals, Inc., the Registrant, Progenics Pharmaceuticals Nevada, Inc. and Excelsior Life Sciences Ireland Limited.                                                                           |
| 10.37.1(9) †   |   | 2010 Agreement Related to Progenics' MNTX In-License, dated February 3, 2011, by and among the University of Chicago, acting on behalf of itself and ARCH Development Corporation, the Registrant, Progenics Pharmaceuticals Nevada, Inc. and Salix Pharmaceuticals, Inc. |
| 10.38(18) †    |   | Stock Purchase and Sale Agreement, dated January 16, 2013, by and between Molecular Insight Pharmaceuticals, Inc., its Stockholders, the Registrant, and Highland Capital Management, L.P., as Stockholders Representative.                                               |
| 10.39(18) †    |   | License Agreement, dated September 1, 2012, by and between FUJIFILM RI Pharma Co., Ltd. and Molecular Insight Pharmaceuticals, Inc.                                                                                                                                       |
| 10.40 †† |   | License Agreement, dated May 2, 2012, between Molecular Insight Pharmaceuticals, Inc., the University of Zurich and the Paul Scherrer Institute.                                                                                                                          |
| 10.41(19)            |   | License Agreement, dated as of December 15, 2000, between Molecular Insight Pharmaceuticals, Inc. and The Board of Governors of the University of Western Ontario.                                                                                                        |
| 10.42(19)            |   | License Agreement, dated as of November 3, 2006, between Molecular Insight Pharmaceuticals, Inc. and Novartis Pharma AG, together with First Amendment, dated January 4, 2007, thereto.                                                                                   |
| 10.43(20)            |   | Controlled Equity OfferingSM Sales Agreement dated as of January 23, 2014, by and between the Registrant and Cantor Fitzgerald & Co. (filed as Exhibit 1.1 to Registration Statement on Form S-3, Commission File No. 333-193521.                                |
| 12.1                 |   | Statement re computation of ratio of earnings (loss) to combined fixed charges and preferred stock dividends.                                                                                                                                                        |
| 21.1                 |   | Subsidiaries of the Registrant.                                                                                                                                                                                                                                           |
| 23.1                 |   | Consent of PricewaterhouseCoopers LLP.                                                                                                                                                                                                                                    |
| 23.2                 |   | Consent of Ernst & Young LLP.                                                                                                                                                                                                                                         |
| 31.1                 |   | Certification of Mark R. Baker, Chief Executive Officer of the Registrant pursuant to 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.                                                                                            |
| 31.2                 |   | Certification of Angelo W. Lovallo, Jr., Vice President, Finance & Treasurer of the Registrant pursuant to 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.                                                                        |
| 32.1                 |   | Certification of Mark R. Baker, Chief Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                             |
| 32.2                 |   | Certification of Angelo W. Lovallo, Jr., Vice President, Finance & Treasurer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                         |
| 101                  |   | Interactive Data File                                                                                                                                                                                                                                                     |
| 101.INS              |   | XBRL Instance Document                                                                                                                                                                                                                                                    |
| 101.SCH              |   | XBRL Taxonomy Extension Schema                                                                                                                                                                                                                                            |
| 101.CAL              |   | XBRL Taxonomy Extension Calculation Linkbase                                                                                                                                                                                                                              |
| 101.LAB              |   | XBRL Taxonomy Extension Label Linkbase                                                                                                                                                                                                                                    |
| 101.PRE              |   | XBRL Taxonomy Extension Presentation Linkbase                                                                                                                                                                                                                             |
| 101.DEF              |   | XBRL Taxonomy Extension Definition Document                                                                                                                                                                                                                               |

|   |   |                                                                                                                                                                                                   |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| *      |   | Exhibits footnoted as previously filed have been filed as an exhibit to the document of the Registrant or other registrant referenced in the footnote below, and are incorporated by reference herein. |
|   |   |                                                                                                                                                                                                   |
| (1)    |   | Previously filed in Current Report on Form 8-K filed on June 13, 2013.                                                                                                                                 |
| (2)    |   | Previously filed in Current Report on Form 8-K filed on March 16, 2012.                                                                                                                                |
| (3)    |   | Previously filed in Registration Statement on Form S-1, Commission File No. 333-13627.                                                                                                                 |
| (4)    |   | Previously filed in Registration Statement on Form S-8, Commission File No. 333-120508.                                                                                                                |
| (5)    |   | Previously filed in Current Report on Form 8-K filed on June 17, 2013.                                                                                                                                 |
| (6)    |   | Previously filed in Current Report on Form 8-K filed on July 8, 2008.                                                                                                                                  |
| (7)    |   | Previously filed in Quarterly Report on Form 10-Q for the quarter ended March 31, 2007.                                                                                                                |
| (8)    |   | Previously filed in Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.                                                                                                                |
| (9)    |   | Previously filed in Quarterly Report on Form 10-Q for the quarter ended June 30, 1999.                                                                                                            |
| (10)   |   | Previously filed in Annual Report on Form 10-K for the year ended December 31, 2004.                                                                                                                   |
| (11)   |   | Previously filed in Annual Report on Form 10-K for the year ended December 31, 2002.                                                                                                              |
| (12)   |   | Previously filed in Current Report on Form 8-K filed on September 20, 2004.                                                                                                                            |
| (13)   |   | Previously filed in Current Report on Form 8-K filed on November 28, 2012.                                                                                                                             |
| (14)   |   | Previously filed in Annual Report on Form 10-K for the year ended December 31, 2005.                                                                                                                   |

----

Table of Contents

| (15)           |   | Previously filed in Quarterly Report on Form 10-Q for the quarter ended June 30, 2006                                                                                                   |
|----------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (16)           |   | Previously filed in Annual Report on Form 10-K for the year ended December 31, 2008.                                                                                                    |
| (17)           |   | Previously filed in Amendment No. 2 to Annual Report on Form 10-K/A for the year ended December 31, 2009.                                                                               |
| (18)           |   | Previously filed in Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.                                                                                                 |
| (19)           |   | Previously filed in Registration Statement on Form S-1, Commission File No. 333-129570 filed by Molecular Insight Pharmaceuticals, Inc.                                                 |
| (20)           |   | Previously incorporated in Current Report on Form 8-K filed on January 24, 2014 by reference to Exhibit 1.1 to Registration Statement on Form S-3, Commission File No. 333-193521. |
|           |   |                                                                                                                                                                                    |
|           |   |                                                                                                                                                                                    |
| †        |   | Confidential treatment granted as to certain portions omitted and filed separately with the Commission.                                                                                 |
| †† |   | Confidential treatment requested as to certain portions omitted and filed separately with the Commission.                                                                               |
| ‡        |   | Management contract or compensatory plan or arrangement.                                                                                                                                |
|           |   |                                                                                                                                                                                    |